StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)

Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –

Amneal Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Amneal Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $175.57M, down 13.7% year over year. For fiscal 2025 it was $186.18M, down 2.4% from the year before. The highest annual figure on record is $201.85M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$186.18M-2.4%
FY2024Dec 31, 2024$190.71M+16.3%
FY2023Dec 31, 2023$163.95M-16.2%
FY2022Dec 31, 2022$195.69M-3.1%
FY2021Dec 31, 2021$201.85M+12.2%
FY2020Dec 31, 2020$179.93M-4.3%
FY2019Dec 31, 2019$188.05M-3.2%
FY2018Dec 31, 2018$194.19M+13.3%
FY2017Dec 31, 2017$171.42M-4.2%
FY2016Dec 31, 2016$179.02M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$39.02M-18.7%
Q1 FY2026Mar 31, 2026$38.38M-4.1%
Q4 FY2025Dec 31, 2025$34.82M-35.8%
Q3 FY2025Sep 30, 2025$63.35M+3.7%
Q2 FY2025Jun 30, 2025$47.96M+33.0%
Q1 FY2025Mar 31, 2025$40.04M+1.9%
Q4 FY2024Dec 31, 2024$54.27M+17.7%
Q3 FY2024Sep 30, 2024$61.10M+47.7%
Q2 FY2024Jun 30, 2024$36.05M-4.6%
Q1 FY2024Mar 31, 2024$39.30M+1.6%
Q4 FY2023Dec 31, 2023$46.09M+10.0%
Q3 FY2023Sep 30, 2023$41.38M-17.6%
Q2 FY2023Jun 30, 2023$37.80M-25.5%
Q1 FY2023Mar 31, 2023$38.69M-26.7%
Q4 FY2022Dec 31, 2022$41.91M-19.2%
Q3 FY2022Sep 30, 2022$50.24M+2.7%
Q2 FY2022Jun 30, 2022$50.75M-4.0%
Q1 FY2022Mar 31, 2022$52.80M+9.6%
Q4 FY2021Dec 31, 2021$51.87M-3.0%
Q3 FY2021Sep 30, 2021$48.93M+9.9%
Q2 FY2021Jun 30, 2021$52.86M+16.0%
Q1 FY2021Mar 31, 2021$48.18M+32.4%
Q4 FY2020Dec 31, 2020$53.46M+11.3%
Q3 FY2020Sep 30, 2020$44.52M+16.8%
Q2 FY2020Jun 30, 2020$45.57M-5.1%
Q1 FY2020Mar 31, 2020$36.38M-32.5%
Q4 FY2019Dec 31, 2019$48.05M-16.1%
Q3 FY2019Sep 30, 2019$38.13M-10.0%
Q2 FY2019Jun 30, 2019$48.02M-4.6%
Q1 FY2019Mar 31, 2019$53.86M+21.8%
Q4 FY2018Dec 31, 2018$57.30M+31.7%
Q3 FY2018Sep 30, 2018$42.35M+2.5%
Q2 FY2018Jun 30, 2018$50.34M+6.7%
Q1 FY2018Mar 31, 2018$44.21M–
Q4 FY2017Dec 31, 2017$43.49M–
Q3 FY2017Sep 30, 2017$41.32M–
Q2 FY2017Jun 30, 2017$47.18M–

More Amneal Pharmaceuticals figures

See a number that looks wrong?